Steris (STE) Receives a Buy from KeyBanc
I'm LongbridgeAI, I can summarize articles.KeyBanc analyst Brett Fishbin maintained a Buy rating on Steris (STE) with a price target of $269.00. This follows Piper Sandler's Buy rating from August 7, while Needham held a Hold rating on August 6.
In a report released today, Brett Fishbin from KeyBanc maintained a Buy rating on Steris, with a price target of $269.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Fishbin covers the Healthcare sector, focusing on stocks such as Resmed, Cooper Co, and Integer Holdings. According to TipRanks, Fishbin has an average return of 0.0% and a 49.33% success rate on recommended stocks.
In addition to KeyBanc, Steris also received a Buy from Piper Sandler’s Jason Bednar in a report issued on August 7. However, on August 6, Needham maintained a Hold rating on Steris (NYSE: STE).